Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.

Abstract

Heterozygous loss-of-function mutations in progranulin (GRN) cause frontotemporal dementia (FTD), a leading cause of early-onset dementia characterized clinically by behavioral, social, and language deficits. There are currently no FDA-approved therapeutics for FTD-GRN, but this has been an active area of investigation, and several approaches are now in clinical trials. Here, we review preclinical development of therapies for FTD-GRN with a focus on testing in mouse models. Since most FTD-GRN-associated mutations cause progranulin haploinsufficiency, these approaches focus on raising progranulin levels. We begin by considering the disorders associated with altered progranulin levels, and then review the basics of progranulin biology including its lysosomal, neurotrophic, and immunomodulatory functions. We discuss mouse models of progranulin insufficiency and how they have been used in preclinical studies on a variety of therapeutic approaches. These include approaches to raise progranulin expression from the normal allele or facilitate progranulin production by the mutant allele, as well as approaches to directly increase progranulin levels by delivery across the blood-brain barrier or by gene therapy. Several of these approaches have entered clinical trials, providing hope that new therapies for FTD-GRN may be the next frontier in the treatment of neurodegenerative disease.

• Authors: Shreya N Kashyap, Nicholas R Boyle, Erik D Roberson
• Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (Neurotherapeutics) Vol. 20 Issue 1 Pg. 140-153 (01 2023) ISSN: 1878-7479 [Electronic] United States
• PMID: 36781744 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: © 2023. The Author(s).

Chemical References

• Progranulins
• Intercellular Signaling Peptides and Proteins

Topics

• Mice
• Animals
• Progranulins (genetics)
• Frontotemporal Dementia (genetics, therapy, metabolism)
• Intercellular Signaling Peptides and Proteins (genetics)
• Neurodegenerative Diseases
• Mutation (genetics)